tofacitinib - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.49 [0.15, 1.62]< 10%1 study (1/-)87.9 %NAnot evaluable crucial-
deaths 0.49 [0.15, 1.62]< 10%1 study (1/-)87.9 %NAnot evaluable crucial-
clinical deterioration 0.54 [0.27, 1.07]< 10%1 study (1/-)96.1 %NAnot evaluable important-
death or ventilation 0.63 [0.41, 0.97]< 10%1 study (1/-)98.2 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.